[Numab Therapeutics AG numab, Drug Innovators, Swiss biotech company, development, antibody-based therapeutics, Swiss, biotech company, biotech, antibody, antibodies, antibody fragment, scFv, variable domain, Fv fragment, antibody discovery, antibody development, drug, drug discovery, drug development, high-affinity, high affinity, drug-like, highly stable, modular design, designed functionality, bi-specific, bispecific, tailored half-life, difficult target, ion channel, GPCR, native display]